Recursion Reports Q4 Revenue of $35.5M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RXRX?
Reports Q4 revenue $35.5M, consensus $24.56M. Cash, cash equivalents and restricted cash were $753.9M as of December 31, 2025 compared to $603.0M as of December 31, 2024. Based on current operating plans and with no additional financing, the Company's expected cash runway extends into early 2028. "Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value," said Najat Khan, CEO & President of Recursion. "Our first AI-enabled clinical proof of concept in FAP and our fifth program milestone achieved with Sanofi reflect the increasing maturity of a deeply integrated model - one that connects biology, chemistry, and clinical development into a continuous learning system. We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than $500M in upfront and progress-based milestone payments earned to date. Pairing bold ambition with disciplined execution, we are building Recursion to compound over time - translating insight into molecules, molecules into medicines, and innovation into measurable impact for patients and shareholders alike."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.670
Low
5.00
Averages
7.75
High
11.00
Current: 3.670
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Pharmaceuticals Q4 2025 Earnings Call Insights
- Financial Transformation: Recursion ended 2025 with $754 million in cash, achieving a 35% year-over-year reduction in operating expenses and actual spending 10% below earlier guidance, indicating significant progress in financial management and enhancing future investment flexibility.
- Clinical Milestone Progress: The company reached its fifth milestone with Sanofi and achieved the first positive clinical proof of concept with FAP, demonstrating the effectiveness of its AI-driven platform in drug development, which may attract more attention for future collaborations and investments.
- Strategic Execution and Outlook: Management expects cash operating expenses for 2026 to be under $390 million, with cash flow projections including over $500 million in partnership inflows, reflecting confidence in advancing clinical programs and partnerships.
- Risks and Challenges: Despite progress in operational efficiency, management highlighted the inherent risks of drug discovery with a 90% failure rate, emphasizing the importance of rapid decision-making and efficient capital allocation to navigate future uncertainties.
See More
Recursion Pharmaceuticals Q4 Earnings Exceed Expectations
- Significant Revenue Growth: Recursion Pharmaceuticals reported total revenue of $35.5 million for Q4 2025, a substantial increase from $4.5 million in the same period last year, exceeding market expectations by nearly $11 million, primarily due to a milestone payment from Roche.
- Annual Performance Improvement: The company's total revenue climbed approximately 27% year-over-year to $74.7 million for the full year, with part of this growth attributed to the financials from the Exscientia acquisition in 2024, indicating successful business expansion.
- Decrease in R&D and SG&A Expenses: Although the net loss per share reached $0.21, surpassing consensus by $0.08, R&D and SG&A expenses fell by about 2% and 56% year-over-year to $95.9 million and $33.7 million, respectively, demonstrating effective cost control measures.
- Strong Liquidity Position: As of December 31, Recursion reported cash and cash equivalents of $743.3 million, a significant increase from $594.4 million a year ago, with projections indicating a cash runway extending into 2028 without the need for additional financing.
See More
Recursion Pharmaceuticals Stock Surges After Strong Earnings Report
- Exceeding Market Expectations: Recursion Pharmaceuticals reported a loss per share of 21 cents, better than the expected loss of 27 cents, with quarterly revenue reaching $35.54 million, significantly surpassing the forecast of $24.59 million, indicating substantial progress in AI applications for drug discovery.
- Strong Stock Surge: The stock price of Recursion Pharmaceuticals rose by 11.33% to $3.93 during Wednesday's trading, reflecting a positive market reaction to its earnings report, although it remains 16.1% and 19.4% below its 100-day and 200-day moving averages, respectively.
- Technical Indicator Analysis: Currently, the stock trades 2.1% above its 20-day simple moving average, but the relative strength index (RSI) stands at 38.97, indicating neutral momentum, while the MACD shows a bearish signal, suggesting potential downward pressure despite the day's gains.
- CEO's Positive Outlook: CEO Najat Khan stated that Recursion has reached an inflection point, demonstrating that AI can not only participate in drug discovery but also generate clinical proof and durable value, laying a foundation for future growth.
See More
Totaligent Forms Joint Venture with GloMed for Biologics Distribution
- Strategic Partnership: Totaligent has signed a binding Letter of Intent with Japan's GloMed Solutions to establish a joint venture that integrates Totaligent's Aetherium medical platform with GloMed's distribution infrastructure, aiming to accelerate biologics adoption in the APAC market, with the transaction expected to close in approximately four weeks.
- Capital Structure Reset: XWELL announced a $31.3 million private placement aimed at repurchasing $5.96 million in outstanding notes and redeeming Series G Preferred Stock, indicating a strategic effort to simplify its balance sheet, with closing expected around February 26.
- AI Drug Discovery Validation: Recursion Pharmaceuticals reported Q4 and full-year 2025 results, highlighting clinical validation of its AI-driven drug discovery platform, with REC-4881 showing 75% efficacy in familial adenomatous polyposis patients, reinforcing the company's leadership in the biotech sector.
- Revenue Growth Expectations: NextPlat projects approximately $55 million in revenue for 2025, with Q4 340B revenue expected to increase over 90%, and anticipates gross margin expansion of 20%-25% in 2026, reflecting a strategic shift towards revenue quality and cost control.
See More
Recursion Pharmaceuticals Q4 2025 Earnings Highlights
- Earnings Beat: Recursion Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.21, beating expectations by $0.08, indicating a positive trend in the company's profitability improvement efforts.
- Significant Revenue Growth: The company achieved revenue of $35.54 million in Q4, a staggering 681.1% year-over-year increase, surpassing market expectations by $10.98 million, reflecting a substantial rise in demand for its products and services.
- Improved Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and restricted cash totaled $753.9 million, up from $603.0 million in the same period of 2024, indicating a continued improvement in financial health.
- Reduced Operating Cash Use: Net cash used in operating activities for Q4 2025 was $46.1 million, significantly down from $115.4 million in Q4 2024, showcasing the company's success in cost control and operational efficiency.
See More
Recursion Pharmaceuticals Q4 Results Exceed Expectations, Shares Surge
- Earnings Beat: Recursion Pharmaceuticals saw a 16% surge in pre-market trading on Wednesday after reporting a Q4 loss of $0.21 per share on revenues of $35.5 million, surpassing Wall Street's expectations of a $0.32 loss and $24.6 million in revenue, indicating a significant improvement in financial performance.
- AI Drug Discovery Breakthrough: CEO Najat Khan stated that Recursion has reached an inflection point, demonstrating not only AI's role in drug discovery but also the potential of an AI-native operating system to generate clinical proof and durable value, laying a strong foundation for future R&D.
- Positive Market Sentiment: Retail sentiment on Stocktwits regarding Recursion Pharmaceuticals trended bullish, reflecting increased investor confidence in the company's future prospects, which may further drive stock price appreciation.
- Enhanced Industry Influence: As the company continues to advance in AI-driven drug discovery, Recursion is poised to gain a more significant position in the biopharmaceutical industry, attracting greater investor interest in its innovative capabilities and market potential.
See More
Recursion Pharmaceuticals Q4 2025 Earnings Call Insights
- Financial Transformation: Recursion ended 2025 with $754 million in cash, achieving a 35% year-over-year reduction in operating expenses and actual spending 10% below earlier guidance, indicating significant progress in financial management and enhancing future investment flexibility.
- Clinical Milestone Progress: The company reached its fifth milestone with Sanofi and achieved the first positive clinical proof of concept with FAP, demonstrating the effectiveness of its AI-driven platform in drug development, which may attract more attention for future collaborations and investments.
- Strategic Execution and Outlook: Management expects cash operating expenses for 2026 to be under $390 million, with cash flow projections including over $500 million in partnership inflows, reflecting confidence in advancing clinical programs and partnerships.
- Risks and Challenges: Despite progress in operational efficiency, management highlighted the inherent risks of drug discovery with a 90% failure rate, emphasizing the importance of rapid decision-making and efficient capital allocation to navigate future uncertainties.
See More
Recursion Pharmaceuticals Q4 Earnings Exceed Expectations
- Significant Revenue Growth: Recursion Pharmaceuticals reported total revenue of $35.5 million for Q4 2025, a substantial increase from $4.5 million in the same period last year, exceeding market expectations by nearly $11 million, primarily due to a milestone payment from Roche.
- Annual Performance Improvement: The company's total revenue climbed approximately 27% year-over-year to $74.7 million for the full year, with part of this growth attributed to the financials from the Exscientia acquisition in 2024, indicating successful business expansion.
- Decrease in R&D and SG&A Expenses: Although the net loss per share reached $0.21, surpassing consensus by $0.08, R&D and SG&A expenses fell by about 2% and 56% year-over-year to $95.9 million and $33.7 million, respectively, demonstrating effective cost control measures.
- Strong Liquidity Position: As of December 31, Recursion reported cash and cash equivalents of $743.3 million, a significant increase from $594.4 million a year ago, with projections indicating a cash runway extending into 2028 without the need for additional financing.
See More
Recursion Pharmaceuticals Stock Surges After Strong Earnings Report
- Exceeding Market Expectations: Recursion Pharmaceuticals reported a loss per share of 21 cents, better than the expected loss of 27 cents, with quarterly revenue reaching $35.54 million, significantly surpassing the forecast of $24.59 million, indicating substantial progress in AI applications for drug discovery.
- Strong Stock Surge: The stock price of Recursion Pharmaceuticals rose by 11.33% to $3.93 during Wednesday's trading, reflecting a positive market reaction to its earnings report, although it remains 16.1% and 19.4% below its 100-day and 200-day moving averages, respectively.
- Technical Indicator Analysis: Currently, the stock trades 2.1% above its 20-day simple moving average, but the relative strength index (RSI) stands at 38.97, indicating neutral momentum, while the MACD shows a bearish signal, suggesting potential downward pressure despite the day's gains.
- CEO's Positive Outlook: CEO Najat Khan stated that Recursion has reached an inflection point, demonstrating that AI can not only participate in drug discovery but also generate clinical proof and durable value, laying a foundation for future growth.
See More
Totaligent Forms Joint Venture with GloMed for Biologics Distribution
- Strategic Partnership: Totaligent has signed a binding Letter of Intent with Japan's GloMed Solutions to establish a joint venture that integrates Totaligent's Aetherium medical platform with GloMed's distribution infrastructure, aiming to accelerate biologics adoption in the APAC market, with the transaction expected to close in approximately four weeks.
- Capital Structure Reset: XWELL announced a $31.3 million private placement aimed at repurchasing $5.96 million in outstanding notes and redeeming Series G Preferred Stock, indicating a strategic effort to simplify its balance sheet, with closing expected around February 26.
- AI Drug Discovery Validation: Recursion Pharmaceuticals reported Q4 and full-year 2025 results, highlighting clinical validation of its AI-driven drug discovery platform, with REC-4881 showing 75% efficacy in familial adenomatous polyposis patients, reinforcing the company's leadership in the biotech sector.
- Revenue Growth Expectations: NextPlat projects approximately $55 million in revenue for 2025, with Q4 340B revenue expected to increase over 90%, and anticipates gross margin expansion of 20%-25% in 2026, reflecting a strategic shift towards revenue quality and cost control.
See More
Recursion Pharmaceuticals Q4 2025 Earnings Highlights
- Earnings Beat: Recursion Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.21, beating expectations by $0.08, indicating a positive trend in the company's profitability improvement efforts.
- Significant Revenue Growth: The company achieved revenue of $35.54 million in Q4, a staggering 681.1% year-over-year increase, surpassing market expectations by $10.98 million, reflecting a substantial rise in demand for its products and services.
- Improved Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and restricted cash totaled $753.9 million, up from $603.0 million in the same period of 2024, indicating a continued improvement in financial health.
- Reduced Operating Cash Use: Net cash used in operating activities for Q4 2025 was $46.1 million, significantly down from $115.4 million in Q4 2024, showcasing the company's success in cost control and operational efficiency.
See More
Recursion Pharmaceuticals Q4 Results Exceed Expectations, Shares Surge
- Earnings Beat: Recursion Pharmaceuticals saw a 16% surge in pre-market trading on Wednesday after reporting a Q4 loss of $0.21 per share on revenues of $35.5 million, surpassing Wall Street's expectations of a $0.32 loss and $24.6 million in revenue, indicating a significant improvement in financial performance.
- AI Drug Discovery Breakthrough: CEO Najat Khan stated that Recursion has reached an inflection point, demonstrating not only AI's role in drug discovery but also the potential of an AI-native operating system to generate clinical proof and durable value, laying a strong foundation for future R&D.
- Positive Market Sentiment: Retail sentiment on Stocktwits regarding Recursion Pharmaceuticals trended bullish, reflecting increased investor confidence in the company's future prospects, which may further drive stock price appreciation.
- Enhanced Industry Influence: As the company continues to advance in AI-driven drug discovery, Recursion is poised to gain a more significant position in the biopharmaceutical industry, attracting greater investor interest in its innovative capabilities and market potential.
See More
